PRME

Prime Medicine (PRME) has achieved significant regulatory and clinical progress, receiving FDA clearance for PM647 targeting alpha-1 antitrypsin deficiency and dosing the first patient in a phase I/II trial of PM577a for Wilson disease. The stock has gained 26% over the past month, outperforming the biotech industry's 2.8% decline, driven by these encouraging developments in its Prime Editing platform for genetic disease treatments.

Prime Medicine announced the first patient dosing in its Phase 1/2 clinical trial of PM577a, an in vivo Prime Editor therapy for H1069Q-mutated Wilson disease. The FDA granted Rare Pediatric Disease designation to PM577, and the company expects initial clinical data in 2027. PM577a is designed as a one-time curative therapy targeting the most prevalent Wilson disease-causing mutation in North America and Europe.